Explore evidence

92.2 %In 2015, Burkina Faso reported a monthly seasonal malaria chemoprevention coverage rate of 92.2%.

Burkina Fasopaludismeobserved 2015HAL · Unilimdocument of 110 observations

45.1 %Vaccine efficacy of RTS,S/AS01 against severe malaria was 45.1% in the intention-to-treat population.

Burkina Fasopaludismepublished 2011The New England journal of medicineeurope_pmcdocument of 7 observationsDOI 10.1056/nejmoa1102287

45.2 %The prevalence of ESBL-producing Enterobacterales was 45.2% (14/31) in Burkina Faso.

Burkina FasoESBL-producing Enterobacteralesobserved November 2013 to March 2017published 2020Frontiers in microbiologyeurope_pmcdocument of 12 observations

38.6 %Of the 57 patients who were febrile on examination, 22 had malaria, representing 38.6%.

Burkina FasopaludismeHAL · Unilimdocument of 83 observations

3.26 odds_ratioHeterozygote males were more competitive than homozygote susceptible males, with an odds ratio of 3.26 and P = 0.006.

Burkina Fasopaludismepublished 2015Heredityeurope_pmcdocument of 6 observations

22.6 %Of the 306 patients, 69 were diagnosed with malaria, representing 22.6%.

Burkina FasopaludismeHAL · Unilimdocument of 83 observations

0.4 proportionThe allele frequency of the L1014S kdr mutation conferring resistance to pyrethroids was 0.4.

Burkina Fasopaludismepublished 2017PloS oneeurope_pmcdocument of 7 observations

7 foldPatients with acute malaria or recovering from malaria had a 7-fold higher risk of presenting polymicrobial bloodstream infections compared to patients with no recent malaria diagnosis.

Burkina Fasopaludisme · polymicrobial bloodstream infectionspublished 2016PLoS neglected tropical diseaseseurope_pmcdocument of 4 observations

23.4 %Of the 73,101 female Anopheles mosquitoes collected, 23.4% (17,083) were captured using CDC_LT.

Burkina Fasopaludismeobserved July 28, 2019 to February 27, 2022HAL · Unilimdocument of 87 observations

11.11 %The prevalence of hepatitis B virus infection in pregnant women in Burkina Faso was 11.11% after adjustment.

Burkina Fasohépatite Bpublished 2018BMC public healtheurope_pmcdocument of 12 observationsDOI 10.1186/s12889-018-5432-7

2.2 %HCV and HBV coinfection was 2.2% among the 462 screened patients at Saint Camille Medical Centre.

Burkina Fasohépatite B · hépatite Cobserved 2012published 2012Pakistan journal of biological sciences : PJBSeurope_pmcdocument of 8 observations

11.7 %The acquisition of immunity against HBV after vaccination was attempted for 11.7% of the screened patients at Saint Camille Medical Centre.

Burkina Fasohépatite Bobserved 2012published 2012Pakistan journal of biological sciences : PJBSeurope_pmcdocument of 8 observations

84.9 %At day 28, the PCR-corrected adequate clinical and parasitological response (ACPR) was 84.9% in the intention-to-treat population receiving the crushed-tablet formulation of dihydroartemisinin/piperaquine phosphate.

Burkina Fasopaludismepublished 2018Antimicrobial agents and chemotherapyeurope_pmcdocument of 10 observations

2.6 per_1000Neonatal mortality rate ranged from 2.6 to 41.6 per 1000 live births.

Burkina Fasomortalité néonataleobserved 2009 to 2014published 2019International journal of public healtheurope_pmcdocument of 7 observations

2.58 odds_ratioHeterozygote RDL(R)/RDL(S) males were more likely to mate than homozygote-resistant males, with an odds ratio of 2.58 and P = 0.007.

Burkina Fasopaludismepublished 2015Heredityeurope_pmcdocument of 6 observations

44.4 %Of 3170 participants, 44.4% in the passive surveillance group reported at least one adverse event after use of artemisinin-based combination therapies.

Burkina Fasopaludismeobserved 2010–2012published 2020Drug design, development and therapyeurope_pmcdocument of 5 observations

3.62 %Mixed-species pairs captured in copula made up 3.62% of mating pairs involving An. coluzzii individuals.

Burkina Fasopaludismepublished 2015Parasites & vectorseurope_pmcdocument of 4 observationsDOI 10.1186/s13071-015-1190-x

27 %A phase 3 clinical trial of RTS,S/AS01 across eleven sub-Saharan African sites demonstrated a vaccine efficacy against clinical malaria of approximately 27% in infants aged 6–12 weeks.

Burkina FasopaludismeHAL · Unilimdocument of 39 observations

The prevalence of HIV seropositivity among young women is higher than for men of the same age in all included Demographic and Health Surveys except for the Burkina Faso DHS.

Burkina FasoVIH/sidapublished 2021Journal of global healthPubMeddocument of 4 observations

17.8 %Using culture, Streptococcus pneumoniae (Spn) accounted for 17.8% of purulent meningitis cases.

Burkina Fasoméningite bactérienneobserved 2009–2010published 2013Medecine et sante tropicaleseurope_pmcdocument of 9 observations

11 %The attributable fraction of fever to malaria was 11% in the dry season in Burkina Faso.

Burkina Fasopaludismeobserved dry seasonpublished 2010Malaria journaleurope_pmcdocument of 20 observationsDOI 10.1186/1475-2875-9-192

CSST/IPTp-SP interacted with birth season and gravidity to reduce the incidence of nonmalarial fevers.

Burkina Fasononmalarial feverspublished 2018The Journal of infectious diseaseseurope_pmcdocument of 3 observationsDOI 10.1093/infdis/jiy140

25.3 titerAt day 180, the PfCSP-specific geometric mean titer (GMT) was 25.3 in the ProC6C-AlOH/Matrix-M group.

Burkina Fasopaludismeobserved D180HAL · Unilimdocument of 39 observations

1,280 casesIn 2023, simple malaria among children under 5 years in the Koudougou health district accounted for 1280 cases and represented 50.01% of malaria cases.

Burkina Fasopaludismeobserved 2023HAL · Unilimdocument of 110 observations

8.4 %La fréquence de la neuropathie périphérique était de 8,4 % chez les personnes vivant avec le VIH au Burkina Faso selon l'étude de Millogo A et al (2008).

Burkina FasoVIH/sidaobserved 2008HAL · Unilimdocument of 747 observations